Search research articles
Contact Us
Filters
Showing results (231-240 of 476) with videos related to
Page
of 48
Sort By:
JMIR Research Protocols
|
August 20, 2016
Designing an Adverse Drug Event Reporting System to Prevent Unintentional Reexposures to Harmful Drugs: Study Protocol for a Multiple Methods Design
David Peddie, Serena S Small, Katherin Badke, et al.
Clinical Pharmacokinetics
|
November 9, 2010
Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel
David S Small, Nagy A Farid, Christopher D Payne, et al.
Neurobiology of Aging
|
September 1, 1992
beta-Amyloid peptide in vitro toxicity: lot-to-lot variability
P C May, B D Gitter, D C Waters, et al.
Journal of Clinical Pharmacy and Therapeutics
|
September 12, 2009
Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease
D S Small, N A Farid, Y G Li, et al.
Journal of Clinical Pharmacology
|
December 21, 2007
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
Nagy A Farid, Christopher D Payne, C Steven Ernest, et al.
Statistics in Medicine
|
November 21, 2023
A mixed model approach to estimate the survivor average causal effect in cluster-randomized trials
Wei Wang, Guangyu Tong, Shashivadan P Hirani, et al.
Trials
|
April 19, 2015
Preference-adaptive randomization in comparative effectiveness studies
Benjamin French, Dylan S Small, Julie Novak, et al.
The American Journal of Managed Care
|
June 26, 2018
Physician practice variation under orthopedic bundled payment
Joshua M Liao, Ezekiel J Emanuel, Gary L Whittington, et al.
Malaria Journal
|
January 7, 2019
Malaria parasite clearance rate regression: an R software package for a Bayesian hierarchical regression model
Saeed Sharifi-Malvajerdi, Feiyu Zhu, Colin B Fogarty, et al.
Pharmacology Research & Perspectives
|
October 31, 2015
Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors
Ellen A Cannady, Ming-Dauh Wang, Stuart Friedrich, et al.
Page
of 48
Search research articles
Search
Showing results (231-240 of 476) with videos related to
Sort By:
Page
of 48
JMIR Research Protocols
|
August 20, 2016
Designing an Adverse Drug Event Reporting System to Prevent Unintentional Reexposures to Harmful Drugs: Study Protocol for a Multiple Methods Design
David Peddie, Serena S Small, Katherin Badke, et al.
Clinical Pharmacokinetics
|
November 9, 2010
Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel
David S Small, Nagy A Farid, Christopher D Payne, et al.
Neurobiology of Aging
|
September 1, 1992
beta-Amyloid peptide in vitro toxicity: lot-to-lot variability
P C May, B D Gitter, D C Waters, et al.
Journal of Clinical Pharmacy and Therapeutics
|
September 12, 2009
Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease
D S Small, N A Farid, Y G Li, et al.
Journal of Clinical Pharmacology
|
December 21, 2007
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
Nagy A Farid, Christopher D Payne, C Steven Ernest, et al.
Statistics in Medicine
|
November 21, 2023
A mixed model approach to estimate the survivor average causal effect in cluster-randomized trials
Wei Wang, Guangyu Tong, Shashivadan P Hirani, et al.
Trials
|
April 19, 2015
Preference-adaptive randomization in comparative effectiveness studies
Benjamin French, Dylan S Small, Julie Novak, et al.
The American Journal of Managed Care
|
June 26, 2018
Physician practice variation under orthopedic bundled payment
Joshua M Liao, Ezekiel J Emanuel, Gary L Whittington, et al.
Malaria Journal
|
January 7, 2019
Malaria parasite clearance rate regression: an R software package for a Bayesian hierarchical regression model
Saeed Sharifi-Malvajerdi, Feiyu Zhu, Colin B Fogarty, et al.
Pharmacology Research & Perspectives
|
October 31, 2015
Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors
Ellen A Cannady, Ming-Dauh Wang, Stuart Friedrich, et al.
Page
of 48